Evaluation of the Efficacy and Safety of Locally Administered HTX-011 for Postoperative Analgesia Following Bunionectomy
A Phase 2, Randomized, Controlled, Multicenter, Evaluation of the Efficacy and Safety of Locally Administered HTX-011, HTX-002, or HTX-009 for Postoperative Analgesia Following Bunionectomy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Anaheim, California, United States, 92801
-
Bakersfield, California, United States, 93311
-
-
Maryland
-
Pasadena, Maryland, United States, 21122
-
-
Texas
-
Houston, Texas, United States, 77027
-
San Antonio, Texas, United States, 78229
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Be male or female 18 years of age or older
Female subjects are eligible only if all of the following apply:
- Not pregnant (female subject of child bearing potential must have a negative serum pregnancy test at screening and negative urine pregnancy test before surgery)
- Not lactating
- Not planning to become pregnant while participating in the study
- Be surgically sterile; or be at least two years post-menopausal; or have a monogamous partner who is surgically sterile; or be practicing double-barrier contraception; or practicing abstinence (must agree to use double-barrier contraception in the event of sexual activity); or using an insertable, injectable, transdermal, or combination oral contraceptive approved by the FDA for greater than 2 months prior to screening visits and commits to the use of an acceptable form of birth control for the duration of the study and for 30 days from completion of the study
- Male subjects must be surgically sterile (biologically or surgically) or commit to the use of a reliable method of birth control for the duration of the study until at least 1 week after the administration of study medication
- Be scheduled to undergo a primary unilateral first metatarsal bunionectomy repair, without collateral procedures, under regional anesthesia
- Subject has not had a contralateral bunionectomy in the non-study foot in the past 3 months
- Have the ability and be willing to comply with the study procedures.
- Must be able to understand study procedures and give informed consent for the conduct for all study procedures, using an IRB approved consent form
Exclusion Criteria:
- Unwilling to sign informed consent or not willing or able to complete all study procedures
- Have a contraindication or be allergic to any medication to be used during the trial period
- Have clinically significant cardiac abnormalities that, in the opinion of the investigator, would pose a health risk to the subject
- Have American Society of Anesthesiologists (ASA) Physical Status classification system category ≥4
- Have clinically significant renal or hepatic abnormalities: for example, AST or ALT > 3x ULN, creatinine > 2x ULN
- Have another pre-existing painful condition that may confound pain assessments
- Have another surgery planned within 30 days of procedure
- Have a known or suspected history of alcohol or drug abuse, or a positive drug screen
- Currently taking analgesics for a chronically painful condition, or has taken long acting opioids within 3 days of surgery, or taken any opioids within 24 hours of scheduled surgery for this study
- Subjects with documented sleep apnea or are on home continuous positive airway pressure (CPAP)
- Subjects who are receiving oxygen therapy at the time of screening
- Have participated in a clinical trial within 30 days of planned surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: HTX-011A: 200 mg
HTX-011A (bupivacaine/meloxicam), 200 mg/6 mg via injection.
|
HTX-011A (bupivacaine/meloxicam), via injection.
|
|
Experimental: HTX-011B: 30 mg
HTX 011B (bupivacaine/meloxicam), 30 mg/0.9 mg via injection.
|
HTX-011B (bupivacaine/meloxicam), via injection or instillation.
|
|
Experimental: HTX-011B : 60 mg
HTX-011B (bupivacaine/meloxicam) 60 mg/1.8
mg via injection or instillation.
|
HTX-011B (bupivacaine/meloxicam), via injection or instillation.
|
|
Experimental: HTX-011B: 120 mg
HTX- 011B (bupivacaine/meloxicam), 120 mg/3.6 mg via injection or instillation.
|
HTX-011B (bupivacaine/meloxicam), via injection or instillation.
|
|
Experimental: HTX-011B: 200 mg
HTX- 011B (bupivacaine/meloxicam), 200 mg/6 mg via injection.
|
HTX-011B (bupivacaine/meloxicam), via injection or instillation.
|
|
Active Comparator: Bupivacaine HCI
Bupivacaine HCI, 50 mg via injection.
|
Bupivacaine HCI, via injection.
|
|
Active Comparator: Saline Placebo
Saline placebo via injection.
|
Saline placebo via injection.
|
|
Experimental: HTX-002, 60 mg
HTX- 002, 60 mg via injection.
|
HTX-002, via injection.
|
|
Experimental: HTX-002, 120 mg
HTX-002, 120 mg via injection.
|
HTX-002, via injection.
|
|
Experimental: HTX-002, 200 mg
HTX-002, 200 mg via injection.
|
HTX-002, via injection.
|
|
Experimental: HTX-009
HTX-009, 3.6 mg via injection.
|
HTX-009, via injection.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean Summed Pain Intensity (SPI) Score Over 24 Hours
Time Frame: 0-24 hours
|
The SPI is derived by summing the pain intensity score weighted by the scheduled time duration.
SPI0-24 will be calculated by summing the Pain intensity (PI) score at the relevant time points weighted by the scheduled time duration since the prior PI assessment as follows: SPI0-24= PI1+PI2+2*PI4+2*PI6+2*PI8+2*PI10+2*PI12+2*PI14+4*PI18+6*PI24.
Min = 0 (if PI=0 at every time) and Max = 240 (if PI=10 at every time).
|
0-24 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pain
- Neurologic Manifestations
- Musculoskeletal Diseases
- Nervous System Diseases
- Postoperative Complications
- Pathologic Processes
- Neurobehavioral Manifestations
- Perceptual Disorders
- Foot Deformities
- Foot Deformities, Acquired
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Bunion
- Pain, Postoperative
- Agnosia
- Organic Chemicals
- Anilides
- Amides
- Aniline Compounds
- Amines
- Bupivacaine
Other Study ID Numbers
Other Study ID Numbers
- HTX-011-C2016-208
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.